Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly cabazitaxel in metastatic castration-resistant prostate cancer after docetaxel
2011-003156-39Phase 2Completed
- Sponsor
- Tampere University Hospital
- Start
- Jul 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Tampere University Hospital. Primary endpoint: Safety of biweekly cabazitaxel. Started Jul 2011; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2011-003156-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003156-39.